GPGustavo Guadagini Perez

Gustavo Guadagini Perez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gustavo Guadagini Perez has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Herbert Leonel de Matos Guedes

    Immunobiotechnology Laboratory, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro

    2 shared publications
  • Alessandra Almeida Filardy

    Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Laboratório de Imunologia Celular, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil

    1 shared publication
  • Alessandra Marcia da Fonseca-Martins

    Instituto de Microbiologia Professor Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    1 shared publication
  • Amilcar Tanuri

    Federal University of Rio de Janeiro

    1 shared publication
  • Ana C. Vicente Santos

    Affiliations Laboratório de Biologia Estrutural de Vírus, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem, Centro Nacional de Biologia Estrutural e Bioimagem (CENABIO), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    1 shared publication
  • Andre Macedo Vale

    Laboratório de Biologia de Linfócitos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro

    1 shared publication

Latest Publications

  • Open Access

    Leishmania amazonensis infection induces IL1β-dependent hyperalgesia, while dampening mechanical allodynia in C57BL/6 mice

    by Gustavo G. Perez, Emanuelle V. de Lima, Leticia S. Antonio, Eduardo Matheus M. Vidal, Raissa R. Christoff, Milla B. Paiva, Antônio José S. Gonçalves, Marcia P. Oliveira, Maria Bellio, Robson Coutinho Silva, et al.

    Leishmaniasis is a group of neglected diseases that cause significant mortality and disability. In Brazil, the most prevalent form is cutaneous leishmaniasis, which is characterized by painless lesions despite intense inflammation and ulceration. While BALB/c mouse models exhibit hypersensitivity to inflammatory stimuli, C57BL/6 mice better mimic human-like lesion progression and nociception. This study aimed to investigate the mechanisms underlying nociception in cutaneous leishmaniasis using the C57BL/6 model. Following infection with L. amazonensis, behavioral and nociceptive tests revealed unaltered mechanical nociception and motor capacity, although thermal hyperalgesia was observed during the chronic phase. Elevated IL-1β production in lesions and upregulation of TRPV1 in dorsal root ganglia (DRG) neurons were detected via ELISA and RT-qPCR. Mice deficient in IL-1β signaling components exhibited increased thermal thresholds, highlighting the role of IL-1β in thermal hyperalgesia during chronic infection. Histological analysis of chronic lesions revealed tissue deformities, indicating desensitization to mechanical and inflammatory stimuli due to nerve terminal alterations and fibroplasia resulting from regenerative processes. Conversely, thermal hyperalgesia in the chronic phase is driven by the effects of IL-1β on thermal nociceptive DRG neurons. These findings suggest that IL-1β and TRPV1 contribute to thermal hyperalgesia, whereas structural changes in lesions underlie mechanical desensitization. This model provides insight into the complex nociceptive mechanisms of cutaneous leishmaniasis.


  • Open Access

    Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum

    by Júlio Souza Dos-Santos, Luan Firmino-Cruz, Alessandra Marcia da Fonseca-Martins, Diogo Oliveira-Maciel, Gustavo Guadagini Perez, Victor A. R. Pereira, Carlos H. Dumard, Francisca H. Guedes-Da-Silva, Ana C. Vicente Santos, Monique dos Santos Leandro, et al.

    The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4 + and CD8 + T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.